Background: Sorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC) but dose-limiting toxicity prevents optimal treatment in a considerable proportion of patients. Large cohort studies have indicated potential efficacy of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in intermediate and advanced HCC and therefore the SARAH trial was initiated to directly compare the efficacy and safety of SIRT with sorafenib. Method: SARAH was a randomised, controlled, open-label, multicentre, investigatorinitiated, phase III trial. Adult patients with locally advanced or recurrent HCC, not amenable to other treatments or after 2 failed rounds of chemoembolisation, were randomised 1:1 to SIRT with Y-90 resin microspheres (SIR-Spheres; Sirtex, North Sydney, Australia) or oral sorafenib 400 mg bid. The primary endpoint was overall survival (OS; Kaplan-Meier analysis). Secondary endpoints included progression-free survival (PFS; Kaplan-Meier analysis), time to radiological progression at any site and in the liver as the first event (competing risk analysis), tumour response, adverse event (AE) rates and quality of life (QoL) measured with the global health status sub-score of the QLQ-C30. Results: Of 459 patients randomised (237 received SIRT; 222 received sorafenib), 67.8% had advanced HCC, 43.6% had chemoembolisation failure and 60.3% had macrovascular invasion, with 33.3% of these having main portal vein involvement. There were no clinically relevant differences between treatment groups at baseline. In the intention-to-treat (ITT) analysis, median OS was 8.0 months and 9.9 months in the SIRT and sorafenib groups, respectively (HR, 1.15; 95% CI, 0.94-1.41; p ¼ 0.18). In the population of 174 SIRT and 206 sorafenib patients that received treatment per protocol (PP), median OS was 9.9 months in both groups (HR, 0.99; 95% CI 0.79-1.24; p ¼ 0.92). Median PFS in the ITT analysis was 4.1 months and 3.7 months in the SIRT and sorafenib groups, respectively (HR, 1.03; 95% CI, 0.85-1.25; p ¼ 0.76). Cumulative incidence of radiological progression in the liver as first event was significantly lower in the SIRT than in the sorafenib group (ITT HR, 0.72; 95% CI, 0.56-0.93; p ¼ 0.014). Objective response rate (complete response or partial response) was significantly higher in the SIRT than in the sorafenib group (19.0% vs. 11.6%, p ¼ 0.042). The number of patients with !1 treatment-related AE was 173 (76.5%) and 203 (94.0%; p < 0.001), including 92 (40.7%) and 136 (63.0%) grade !3 AEs (p < 0.001) in the SIRT and sorafenib groups, respectively. QoL was significantly better in the SIRT than in the sorafenib group (group effect p ¼ 0.005; time effect p < 0.001), and the between-group difference tended to increase with time (group-time interaction p ¼ 0.045). Conclusions: OS was not statistically different between sorafenib and SIRT in patients with locally advanced or recurrent HCC. However, liver-directed SIRT was significantly more effective than daily sorafenib systemic treatment in controlling tumour progression in the liver, provides a better tumour response rate, produced fewer treatmentrelated adverse events, and maintained a better QoL over the first 12 months of treatment.
Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin (also known as BBI-608 and BBI608), a first-in-class cancer stemness inhibitor in development, was identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al, PNAS 112(6):1839 , 2015 . Preclinical studies suggest that napabucasin sensitizes heterogeneous cancer cells to chemotherapy and targeted agents. Methods: A phase Ib/II multi-center study in mPDAC pts was performed to confirm the RP2D, PK profile and evidence of anticancer activity of napabucasin in combination with nabPTX and Gem. Pts received napabucasin 240 mg BID with weekly nabPTX 125 mg/m 2 and gem 1000 mg/m 2 for 3 out of every 4 weeks until disease progression or other discontinuation criterion. Results: Of 66 intent to treat (ITT) pts enrolled, 49 (74%) were treatment-naïve and 17 (26%) received (neo)/adjuvant treatment. There were no significant PK interactions, dose-limiting or unexpected toxicities. Most common adverse events (AEs) included grade 1 diarrhea, nausea, fatigue, neuropathy, grade 2 alopecia, and grade 3 neutropenia. Among pts who received RECIST evaluation (55), disease control (DCR; CRþPRþSD) was observed in 51 (93%), with a total ORR of 55%, including CR (4%) and PR (51%). Of 11 pts with non-evaluable disease, treatment stopped due to compliance (4), consent withdrawal (3), clinical PD (1), toxicity (1), insurance (1) and death (1). Among 66 ITT pts, DCR was observed in 51 (77%), with 2 CR (3%) and 28 PR (42%). Maturing median progression free survival and overall survival (OS) in ITT pts is >7.1 and >10.7 m, respectively. Conclusions: This study showed that napabucasin can be combined with nab-PTX and gem, with encouraging signs of efficacy in mPDAC currently being confirmed in a phase 3 study (NCT02993731).
Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI 1/2 bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts) 
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